Navigation Links
Heartware Schedules First Quarter Conference Call And Webcast
Date:5/3/2012

FRAMINGHAM, Mass. and SYDNEY, May 3, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2012, at 5:00 p.m. U.S. Eastern Daylight Time on Thursday, May 10, 2012 (being 7:00 a.m. Australian Eastern Standard Time, on May 11, 2012). The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the quarter and business outlook.  The call may be accessed by dialing 1-888-549-7704 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9810.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare First Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  The HeartWare System has received CE Marking in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
3. HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
4. HeartWare Schedules Fourth Quarter Conference Call and Webcast
5. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
6. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
8. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
9. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
10. HeartWare International Announces Planned Departure of Chief Financial Officer
11. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Cardiology devices segment is anticipated to ... The Cardiology Devices segment is likely to create absolute ... in 2018 over 2017. By the end of 2027, Cardiology ... to US$ 700 Mn, expanding at a CAGR of 18.4% ... Asia Pacific reprocessed medical devices market ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... today released the podcast, “Make Plans for MACRA,” highlighting the impact ... the physician's office and how physicians and other clinicians are reimbursed for the ...
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. By ... to a patient’s remote health progress, empowering the patient to take direct responsibility for ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... Miami ... anniversary as a dentist. , “I could have never imagined back in 1991 that ... personally,” said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered ...
Breaking Medicine News(10 mins):